This is a preview of subscription content, log in via an institution to check access.
Reference
Zhang Y, et al. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR(+)/HER2(-) Metastatic Breast Cancer From the US and Chinese Perspectives. Clinical Therapeutics : 17 May 2019. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.04.033
Rights and permissions
About this article
Cite this article
Palbociclib not cost effective in metastatic breast cancer. PharmacoEcon Outcomes News 829, 18 (2019). https://doi.org/10.1007/s40274-019-5932-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5932-4